Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02638701 · ClinicalTrials.gov registry record · Phase 1

Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

A Phase 1 study of Stroke and Vasculitis, sponsored by University of California, San Francisco.

Recruiting
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT02638701: Recruiting Phase 1 study of Stroke and Vasculitis, sponsored by University of California, San Francisco.

NCT02638701 is a Phase 1 study of Stroke and Vasculitis that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 8 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02638701, a Phase 1 study of Stroke and Vasculitis, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

Patients harboring dolichoectactic vertebrobasilar (DVB) aneurysms are at risk of suffering SAH, ischemic stroke, and/or brainstem compression and many patients are not offered invasive treatment due to the futility of existing surgical methods. Consequently, there is demand for development of medical therapy for DVB aneurysms

Primary Outcome

Our primary outcome for assessing the effectiveness of the infliximab treatment will be the reduction in aneurysm volume over the treatment course based on the 0 and 12 month MR scans. DVB aneurysm volume will be assessed by review of standardized 1.5 mm slices in the axial plane. The contour of the aneurysm using time-of-flight MR angiography sequences will generate a cross-sectional area at each slice level. The volume will be estimated by summing the imputed volume of each slice. Standard T1-

Conditions Studied

Stroke Vasculitis Aneurysm Tumor Necrosis Factor-alpha

Interventions

  • DRUG Infliximab

Study Locations (1)

California

  • UCSF Medical Center - San Francisco

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2024-10-01
Est. Completion 2027-12
Phase Phase 1
University of California, San Francisco

1,713 total trials

What NCT02638701 shows while recruiting

NCT02638701 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower).

The record links to 4 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which Infliximab is the first listed.

NCT02638701 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02638701 about?

NCT02638701 is a clinical study titled "Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms". Patients harboring dolichoectactic vertebrobasilar (DVB) aneurysms are at risk of suffering SAH, ischemic stroke, and/or brainstem compression and many patients are not offered invasive treatment due to the futility of existing surgical methods. Consequently, there is demand for development of medic...

What is the current status of trial NCT02638701?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-10-01. Estimated completion is 2027-12.

What conditions does trial NCT02638701 study?

This clinical trial studies the following conditions: Stroke, Vasculitis, Aneurysm, Tumor Necrosis Factor-alpha.

What interventions are being tested in trial NCT02638701?

The interventions under investigation include: Infliximab (DRUG).

Who is sponsoring clinical trial NCT02638701?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02638701 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02638701's enrollment target sits among peer trials

8 427th of 454 higher than 26 of 454 other Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT02638701

Source: ClinicalTrials.gov NCT02638701, the US trial registry maintained by the National Library of Medicine. NCT02638701 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.